Bepirovirsen, developed by GlaxoSmithKline (GSK), is a 2-MOE-modified ASO that targets all HBV RNAs, promoting RNase H-mediated RNA degradation, reducing HBV replication, and inhibiting HBsAg production
There were inconsistent and nonsignificant reductions in SLC7A11 (Figure 3, D and E, and Supplemental Figure 2, B and C)
All prices include consumption tax
These complications may reflect deteriorating baseline health, immune dysregulation, suboptimal therapeutic responses, or the cumulative burden of repeated invasive procedures
[DOI] [PMC free article] [PubMed] [Google Scholar] 818
In practice, RUO is appropriate for bench experiments, preclinical animal models, and method development, but it does not cover clinical trials or any human administration